Ypsomed Holding AG
YPSN
Κατάταξη σε μετοχές
#2948
Ypsomed Holding AG, together with its subsidiaries, develops, manufactures, and... Ypsomed Holding AG, together with its subsidiaries, develops, manufactures, and sells injection and infusion systems for safe and simple self-medication companies. The company operates through three segments: Ypsomed Delivery Systems, Ypsomed Diabetes Care, and Others. The Ypsomed Delivery Systems segment provides various injection systems, such as pen injectors, auto-injectors, and wearable injectors, as well as other smart devices. This segment offers its products under the YDS brand. The Ypsomed Diabetes Care segment sells and trades in insulin pumps, infusion sets, pen needles, blood glucose monitoring systems, accessories, and other day-to-day items for diabetics. This segment offers its products under the mylife brand name. The company offers precision turned parts; and contract manufacturing and other services. It markets its products through pharmaceutical partners, as well as through its own distribution network and independent distributors. It operates in Switzerland, Europe, North America, and internationally. Ypsomed Holding AG was founded in 1984 and is headquartered in Burgdorf, Switzerland.
Τιμή μετοχής
$469.39
Κεφαλαιοποίηση
$6.17B
Αλλαγή (1 ημέρα)
1.63%
Αλλαγή (1 έτος)
18.98%
Χώρα
CH
Εμπόριο Ypsomed Holding AG (YPSN)
Κατηγορία
Healthcare
Έσοδα για την Ypsomed Holding AG (YPSN)
Έσοδα τον Oct 2026 TTM: 0
Σύμφωνα με τις τελευταίες οικονομικές αναφορές της Ypsomed Holding AG, τα τρέχοντα έσοδα της εταιρείας (TTM) είναι 0. Το 2026, η εταιρεία είχε έσοδα 0 ίσο με τα έσοδα του έτους 2026, τα οποία ήταν 0. Τα έσοδα είναι το συνολικό ποσό που παράγει μια εταιρεία από τις πωλήσεις προϊόντων ή υπηρεσιών. Σε αντίθεση με τα κέρδη, δεν αφαιρούνται έξοδα.
Ιστορικό εσόδων για την Ypsomed Holding AG από 2002 έως 2026
Έσοδα στο τέλος κάθε έτους
| Έτος | Έσοδα | Αλλαγή |
|---|---|---|
| 2025 | $847.04M | 39.34% |
| 2024 | $607.88M | 11.82% |
| 2023 | $543.61M | 7.97% |
| 2022 | $503.49M | 17.75% |
| 2021 | $427.58M | 4.29% |
| 2020 | $409.99M | -10.08% |
| 2019 | $455.95M | -6.76% |
| 2018 | $489.00M | 25.91% |
| 2017 | $388.37M | 10.90% |
| 2016 | $350.19M | 10.82% |
| 2015 | $316.01M | 1.22% |
| 2014 | $312.21M | 21.22% |
| 2013 | $257.56M | -6.31% |
| 2012 | $274.90M | 3.86% |
| 2011 | $264.69M | 9.99% |
| 2010 | $240.64M | 0.57% |
| 2009 | $239.28M | -17.28% |
| 2008 | $289.26M | 26.94% |
| 2007 | $227.87M | -4.32% |
| 2006 | $238.15M | 17.72% |
| 2005 | $202.31M | 38.65% |
| 2004 | $145.92M | 43.99% |
| 2003 | $101.34M | 69.52% |
| 2002 | $59.78M | 0.00% |
Έσοδα για παρόμοιες εταιρείες ή ανταγωνιστές
| Εταιρεία | Έσοδα | Διαφορά Εσόδων | Χώρα |
|---|---|---|---|
| $6.04B | - |
IE
|
|
| - | - |
CN
|
|
| - | - |
CH
|
|
| - | - |
CN
|
|
| $352.16M | - |
KR
|
